We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Anticipates Slow, Rocky Start for Biosimilars Pathway: Woodcock
FDA Anticipates Slow, Rocky Start for Biosimilars Pathway: Woodcock
September 14, 2012
The FDA is projecting a sluggish start for its new biosimilars approval pathway.